⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked stocksUnlock stocks

DSS stock touches 52-week low at $0.85 amid market challenges

Published 19/12/2024, 17:40
DSS stock touches 52-week low at $0.85 amid market challenges
DSS
-

Document Security Systems Inc (NYSE:DSS) shares have hit a 52-week low, trading at $0.85, as the company faces a tumultuous market environment. With a beta of 1.75 indicating high volatility, the stock has declined significantly, showing a 1-year total return of -65.36%. The company’s financial health score from InvestingPro is rated as WEAK, with EBITDA at -$17.2M for the last twelve months. Investors are closely monitoring the company’s performance, seeking signs of a turnaround that could potentially reverse the downward trend. The 52-week low serves as a critical juncture for DSS, as market participants consider the stock’s future trajectory. With revenue declining 17.43% and operating with a moderate debt-to-equity ratio of 1.24, analysts anticipate continued sales decline this year. InvestingPro subscribers have access to 12 additional investment insights about DSS that could help inform investment decisions.

In other recent news, DSS Inc. shareholders held an annual meeting, electing seven directors and ratifying the appointment of Grassi & Co. Certified Public Accountants, P.C. as their independent registered public accounting firm for the fiscal year ending December 31, 2024. The election saw considerable support, with the least amount of votes in favor going to Lim Sheng Hon Danny, and the decision to appoint Grassi & Co. was nearly unanimous. In addition to these developments, DSS Inc. has restated its 2023 financial results due to inaccuracies resulting from a transaction involving Sharing Service Global Corporation. The improper recording led to an overstated loss of approximately $23.5 million. Furthermore, the company announced a change in its executive leadership, appointing Jason Grady as Interim CEO, as former CEO Frank D. Heuszel transitions to a role at Impact Biomedical. These are all recent developments within DSS Inc., reflecting the company’s internal decisions and ongoing evolution.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.